189 related articles for article (PubMed ID: 15133777)
1. Benefit the patient, manage the risk: a system goal.
Califf RM
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):269-76. PubMed ID: 15133777
[No Abstract] [Full Text] [Related]
2. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
3. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.
Powers JH; Ross DB; Brittain E; Albrecht R; Goldberger MJ
Clin Infect Dis; 2002 Mar; 34(6):879-81. PubMed ID: 11850875
[No Abstract] [Full Text] [Related]
4. Errors in 'Trials and error'.
Miller DD
Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048
[No Abstract] [Full Text] [Related]
5. Accelerated approval dust begins to settle.
Mullard A
Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
[No Abstract] [Full Text] [Related]
6. Moment of reckoning.
Wadman M
Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
[No Abstract] [Full Text] [Related]
7. Industry looks to buck bias in emerging 'adaptive' designs.
Torres C
Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
[No Abstract] [Full Text] [Related]
8. How vaccines are developed.
Douglas RG
Curr Clin Top Infect Dis; 1994; 14():192-204. PubMed ID: 8086115
[No Abstract] [Full Text] [Related]
9. Translation of cancer immunotherapies.
Skipper J; Hoffman EW; O'Donnell-Tormey J; Old LJ
Nat Med; 2004 Nov; 10(11):1154-5; author reply 1155. PubMed ID: 15516901
[No Abstract] [Full Text] [Related]
10. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
11. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
12. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
13. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
Peck CC; Rubin DB; Sheiner LB
Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
[No Abstract] [Full Text] [Related]
14. Challenges associated with the development, manufacturing, and delivery of cellular medicines.
Preti RA
Cancer J; 2001; 7 Suppl 2():S62-6. PubMed ID: 11777266
[TBL] [Abstract][Full Text] [Related]
15. Advancing Alzheimer's disease drug review as a national priority.
Perry DP
Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
[TBL] [Abstract][Full Text] [Related]
16. Trends in development and approval times for new therapeutics in the United States.
Reichert JM
Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
[TBL] [Abstract][Full Text] [Related]
17. From laboratory to medicine cabinet.
Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
[TBL] [Abstract][Full Text] [Related]
18. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
19. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
20. Disease models.
Gobburu J
Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
[No Abstract] [Full Text] [Related]
[Next] [New Search]
